Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Progenitor Cell Therapy (PCT), a subsidiary of NeoStem, has acheived compliance with the FACT-JACIE International Standards for cellular therapy product collection, processing and administration, and has received FACT accreditation for its processing facilities based on inspections by FACT at PCT's facilities in Allendale, New Jersey and Mountain View, California.
Subscribe to our email newsletter
In December 1994, the International Society for Cellular Therapy (ISCT) and the American Society for Blood and Marrow Transplantation (ASBMT) merged their standards into a single document covering all aspects of hematopoietic cell therapy (collection, processing, and transplantation).
The two societies established FACT to develop a voluntary Inspection and Accreditation Program based on the joint standards.
FACT promotes quality medical and laboratory practice of cellular therapy through its peer-developed standards and voluntary inspection and accreditation program.
The accreditation process involved the submission of documentation to demonstrate compliance to standards and subsequent on-site inspections conducted by inspectors qualified by training and experience in cellular therapy.
FACT-JACIE standards were developed in 2006 by the Foundation for the Accreditation of Cellular Therapy and the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and the European Group for Blood and Marrow Transplantation (EBMT).
PCT president and chief scientific officer Robert Preti said the accreditation allows them to represent to clients and prospective clients that doing business with PCT accelerates the pathway toward commercialization of their cell therapy products in the most cost-effective manner.